Limiting access to non–vitamin K antagonist oral anticoagulants through step therapy and prior authorization may exacerbate current underuse of anticoagulants and increase the risk of stroke in patients with newly diagnosed atrial fibrillation.
Bo Zhou, PhD
Advertisement
Articles by Bo Zhou, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
FDA Panel Backs 6 Peptides for Compounding
2
Teclistamab-Talquetamab Combo Cuts Myeloma Progression Risk by 89%
3
Oncology Leaders Call for Greater Collaboration to Advance Precision Medicine, Innovative Cancer Care
4
FAQs: Cyclospora Recovery, Treatment, and Outbreak Prevention Strategies
5